La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Zhongzhi Pharmaceutical Holdings Crescita futura

Future criteri di controllo 0/6

Al momento non disponiamo di una copertura analitica sufficiente per prevedere la crescita e il fatturato di Zhongzhi Pharmaceutical Holdings.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	9.2%
Tasso di crescita dei ricavi	n/a
Rendimento futuro del capitale proprio	n/a
Copertura analitica	None
Ultimo aggiornamento	n/a

Aggiornamenti recenti sulla crescita futura

Recent updates

Little Excitement Around Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) Earnings As Shares Take 26% Pounding

Aug 22

Calculating The Intrinsic Value Of Zhongzhi Pharmaceutical Holdings Limited (HKG:3737)

Jun 19

Most Shareholders Will Probably Agree With Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) CEO Compensation

May 10

Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Reducing Its Dividend To CN¥0.03

May 05

Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Reducing Its Dividend To CN¥0.03

Apr 21

Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) Prospects Need A Boost To Lift Shares

Feb 01

These 4 Measures Indicate That Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Using Debt Reasonably Well

May 24

Is Zhongzhi Pharmaceutical Holdings (HKG:3737) A Risky Investment?

Aug 26

Zhongzhi Pharmaceutical Holdings (HKG:3737) Has A Pretty Healthy Balance Sheet

Apr 28

These 4 Measures Indicate That Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Using Debt Reasonably Well

Jun 11

Investors Met With Slowing Returns on Capital At Zhongzhi Pharmaceutical Holdings (HKG:3737)

May 06

Zhongzhi Pharmaceutical Holdings (HKG:3737) Strong Profits May Be Masking Some Underlying Issues

Apr 21

Do Zhongzhi Pharmaceutical Holdings's (HKG:3737) Earnings Warrant Your Attention?

Mar 29

The Zhongzhi Pharmaceutical Holdings (HKG:3737) Share Price Has Gained 50% And Shareholders Are Hoping For More

Mar 05

Is Zhongzhi Pharmaceutical Holdings Limited's(HKG:3737) Recent Stock Performance Tethered To Its Strong Fundamentals?

Feb 15

What Is The Ownership Structure Like For Zhongzhi Pharmaceutical Holdings Limited (HKG:3737)?

Jan 14

Would Zhongzhi Pharmaceutical Holdings Limited (HKG:3737) Be Valuable To Income Investors?

Dec 27

If You Like EPS Growth Then Check Out Zhongzhi Pharmaceutical Holdings (HKG:3737) Before It's Too Late

Dec 14

Did You Miss Zhongzhi Pharmaceutical Holdings' (HKG:3737) 31% Share Price Gain?

Nov 30

Is Zhongzhi Pharmaceutical Holdings Limited's(HKG:3737) Recent Stock Performance Tethered To Its Strong Fundamentals?

Nov 17

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché Zhongzhi Pharmaceutical Holdings non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

SEHK:3737 - Stime future degli analisti e dati finanziari passati (CNY Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
6/30/2024	2,044	111	-22	169	N/A
3/31/2024	2,047	137	-46	135	N/A
12/31/2023	2,050	163	-70	102	N/A
9/30/2023	2,062	164	18	168	N/A
6/30/2023	2,074	164	106	234	N/A
3/31/2023	1,950	135	151	259	N/A
12/31/2022	1,826	106	195	285	N/A
9/30/2022	1,766	84	147	263	N/A
6/30/2022	1,706	63	98	242	N/A
3/31/2022	1,726	57	44	210	N/A
12/31/2021	1,747	52	-9	178	N/A
9/30/2021	1,750	93	-46	132	N/A
6/30/2021	1,753	133	-83	86	N/A
3/31/2021	1,678	136	-54	90	N/A
12/31/2020	1,604	139	-25	93	N/A
9/30/2020	1,524	133	29	120	N/A
6/30/2020	1,444	128	82	147	N/A
3/31/2020	1,393	121	92	157	N/A
12/31/2019	1,342	115	102	168	N/A
9/30/2019	1,282	106	88	160	N/A
6/30/2019	1,221	97	75	152	N/A
3/31/2019	1,182	91	39	116	N/A
12/31/2018	1,142	85	4	80	N/A
9/30/2018	1,106	82	-15	55	N/A
6/30/2018	1,070	79	-35	29	N/A
3/31/2018	1,007	74	N/A	40	N/A
12/31/2017	945	70	N/A	51	N/A
9/30/2017	874	65	N/A	52	N/A
6/30/2017	803	60	N/A	53	N/A
3/31/2017	767	57	N/A	51	N/A
12/31/2016	730	54	N/A	49	N/A
9/30/2016	715	52	N/A	41	N/A
6/30/2016	700	50	N/A	34	N/A
3/31/2016	694	65	N/A	45	N/A
12/31/2015	688	81	N/A	56	N/A
9/30/2015	671	91	N/A	80	N/A
6/30/2015	655	101	N/A	104	N/A
3/31/2015	625	94	N/A	113	N/A
12/31/2014	596	87	N/A	122	N/A
12/31/2013	483	38	N/A	45	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista 3737 è superiore al tasso di risparmio ( 2.3% ).

Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di 3737 cresceranno più velocemente del mercato Hong Kong

Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di 3737 cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di 3737 cresceranno più rapidamente del mercato Hong Kong.

Ricavi ad alta crescita: Dati insufficienti per determinare se si prevede che i ricavi di 3737 cresceranno più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di 3737 è previsto essere elevato tra 3 anni

Zhongzhi Pharmaceutical Holdings Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Zhongzhi Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2024

Zhongzhi Pharmaceutical Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023

Zhongzhi Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended June 30, 2023

Zhongzhi Pharmaceutical Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2022

Zhongzhi Pharmaceutical Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2021

Recent updates

Zhongzhi Pharmaceutical Holdings Limited Announces Resignation of Peng Zhiyun as Non-Executive Director

New minor risk - Profit margin trend

First half 2024 earnings released: EPS: CN¥0.099 (vs CN¥0.16 in 1H 2023)

Little Excitement Around Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) Earnings As Shares Take 26% Pounding

New minor risk - Market cap size

Zhongzhi Pharmaceutical Holdings Limited to Report First Half, 2024 Results on Aug 23, 2024

Zhongzhi Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2024

Calculating The Intrinsic Value Of Zhongzhi Pharmaceutical Holdings Limited (HKG:3737)

Now 20% undervalued after recent price drop

Zhongzhi Pharmaceutical Holdings Limited Approves the Declaration and Payment of Final Dividend

Upcoming dividend of HK$0.03 per share

Most Shareholders Will Probably Agree With Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) CEO Compensation

Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Reducing Its Dividend To CN¥0.03

Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Reducing Its Dividend To CN¥0.03

Zhongzhi Pharmaceutical Holdings Limited, Annual General Meeting, May 17, 2024

Chairman recently bought HK$4.0m worth of stock

Full year 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.13 in FY 2022)

Final dividend of HK$0.03 announced

Zhongzhi Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Mar 22, 2024

Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) Prospects Need A Boost To Lift Shares

Zhongzhi Pharmaceutical Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023

Chairman recently bought HK$1.4m worth of stock

Zhongzhi Pharmaceutical Holdings Limited Approves Interim Dividend

Upcoming dividend of HK$0.06 per share at 8.8% yield

Chairman recently bought HK$467k worth of stock

First half 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.091 in 1H 2022)

Chairman recently bought HK$135k worth of stock

Chairman recently bought HK$955k worth of stock

First half 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.091 in 1H 2022)

Zhongzhi Pharmaceutical Holdings Limited Proposes Interim Dividend for the Six Months Ended 30 June 2023, Payable on 2 November 2023

Investor sentiment improves as stock rises 15%

Zhongzhi Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 23, 2023

Zhongzhi Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended June 30, 2023

These 4 Measures Indicate That Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Using Debt Reasonably Well

Zhongzhi Pharmaceutical Holdings Limited Approves the Declaration and Payment of Special Dividend

Upcoming dividend of HK$0.09 per share at 5.4% yield

Full year 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.062 in FY 2021)

Zhongzhi Pharmaceutical Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Deputy GM & Executive Director recently bought HK$229k worth of stock

Is Zhongzhi Pharmaceutical Holdings (HKG:3737) A Risky Investment?

First half 2022 earnings released: EPS: CN¥0.091 (vs CN¥0.081 in 1H 2021)

Zhongzhi Pharmaceutical Holdings Limited to Report First Half, 2022 Results on Aug 25, 2022

Chairman recently bought HK$177k worth of stock

Zhongzhi Pharmaceutical Holdings (HKG:3737) Has A Pretty Healthy Balance Sheet

Chairman recently bought HK$448k worth of stock

Less than half of directors are independent

Zhongzhi Pharmaceutical Holdings Limited, Annual General Meeting, May 20, 2022

Investor sentiment improved over the past week

Chairman recently bought HK$925k worth of stock

Investor sentiment improved over the past week

Chairman recently bought HK$1.8m worth of stock

Zhongzhi Pharmaceutical Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2021

Investor sentiment improved over the past week

First half 2021 earnings released: EPS CN¥0.081 (vs CN¥0.086 in 1H 2020)

These 4 Measures Indicate That Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Using Debt Reasonably Well

Investors Met With Slowing Returns on Capital At Zhongzhi Pharmaceutical Holdings (HKG:3737)

Zhongzhi Pharmaceutical Holdings (HKG:3737) Strong Profits May Be Masking Some Underlying Issues

Full year 2020 earnings released: EPS CN¥0.17 (vs CN¥0.14 in FY 2019)

Do Zhongzhi Pharmaceutical Holdings's (HKG:3737) Earnings Warrant Your Attention?

Full year 2020 earnings released: EPS CN¥0.17 (vs CN¥0.14 in FY 2019)

Investor sentiment deteriorated over the past week

Zhongzhi Pharmaceutical Holdings Limited to Report Fiscal Year 2020 Results on Mar 24, 2021

The Zhongzhi Pharmaceutical Holdings (HKG:3737) Share Price Has Gained 50% And Shareholders Are Hoping For More

Is Zhongzhi Pharmaceutical Holdings Limited's(HKG:3737) Recent Stock Performance Tethered To Its Strong Fundamentals?

New 90-day high: HK$1.76

What Is The Ownership Structure Like For Zhongzhi Pharmaceutical Holdings Limited (HKG:3737)?

Would Zhongzhi Pharmaceutical Holdings Limited (HKG:3737) Be Valuable To Income Investors?